Clinical and laboratory characterization of a large cohort of patients with Castleman disease retrospectively collected from a single center

Leukemia and Lymphoma

Volumn 50, Issue 8, 2009, Pages 1308-1317

  Dong, Yujun ^a   Na, Jia ^a   Lv, Jicheng ^a   Wang, Rengui ^a   Chen, Xixue ^a   Li, Nan ^a   Ren, Hanyun ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Cytokine production and paraneoplastic conditions; morphology; prognostication

Indexed keywords

BRONCHODILATING AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GLUCOCORTICOID; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; VINCRISTINE;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGED; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BRONCHIOLITIS OBLITERANS; CHINESE; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE CLASSIFICATION; FEMALE; HEMATOPOIETIC SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; INFORMATION PROCESSING; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; MULTI CENTRIC CASTLEMAN DISEASE; NEPHRITIS; NEPHROTIC SYNDROME; OVERALL SURVIVAL; PARANEOPLASTIC PEMPHIGUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN DISEASE; THROMBOCYTOPENIA; UNI CENTRIC CASTLEMAN DISEASE; BLOOD CLOTTING DISORDER; CHILD; CHINA; CLASSIFICATION; FOLLOW UP; INFECTION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PARANEOPLASTIC SYNDROME; PATHOLOGY; PEMPHIGUS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICS; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; BLOOD COAGULATION DISORDERS; BRONCHIOLITIS OBLITERANS; CHILD; CHINA; FEMALE; FOLLOW-UP STUDIES; GIANT LYMPH NODE HYPERPLASIA; HOSPITALS, UNIVERSITY; HUMANS; INFECTION; KAPLAN-MEIERS ESTIMATE; KIDNEY DISEASES; MALE; MIDDLE AGED; PARANEOPLASTIC SYNDROMES; PEMPHIGUS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 77649326100     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190903060095     Document Type: Article

References (39)

1. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph node hyperplasia resembling thymoma. Cancer 1956;9:822-830.
2. Herrada J, Cabanillas F, Rice L, et al. The clinical behavior of localized and multicentric Castleman disease. Ann Intern 1998;128:657-662. (Pubitemid 28169643)
3. Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentricand multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer 1999;85:706-717. (Pubitemid 29075292)
4. Nikolskaia OV, Nousari CH, Anhalt GJ. Paraneoplastic pemphigus in association with Castleman's disease. Br J Dermatol 2003;149:1143-1151. (Pubitemid 38058089)
5. Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Dermatol 2005;129:3-17. (Pubitemid 40524047)
6. Mylona EE, Baraboutis IG, Lekakis LJ, et al. Multicentric Castleman's disease in HIV infection: a systematic review of the literature. AIDS Rev 2008;10:25-35. (Pubitemid 351524049)
7. Wang L, Bu DF, Yang Y, et al. Castleman's tumours and production of autoantibody in paraneoplastic pemphigus. Lancet 2004;363:525-531. (Pubitemid 38229453)
8. Zhu XJ, Wang J, Chen XX, et al. Castleman's disease complicating with paraneoplastic pemphigus - a report of 10 cases. Chinese J Dermatol 2005;38:745-747.
9. Lv JC, Zhang H, Zhou FD, et al. Anti-glomerular basement membrane disease associated with Castleman's disease. Am J Med Sci 2009;337:206-209.
10. Greer JP, Macon WR, McCurley TL, et al. Non-Hodgkin's lymphoma. In: Lee GR, Foerster J, Luken J, et al., editors. Witrobe's Clinical Hematology. Baltimore, PA: Williams & Wilkins; 1999. p 2463.
11. Wang J, Zhu X, Li R, et al. Paraneoplastic pemphigus associated with Castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China. Arch Dermatol 2005;141:1285-1293. (Pubitemid 41498927)
12. Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990;323:1729-1735.
13. Jansen T, Plewig G, Anhalt GJ. Paraneoplastic pemphigus with clinical features of erosive lichen planus associated with Castleman's tumor. Dermatology 1995;190:245-250.
14. Ruggieri G, Barsotti P, Coppola G, et al. Membranous nephropathy associated with giant lymph node hyperplasia. A case report with histological and ultrastructural studies. Am J Nephrol 1990;10:323-328. (Pubitemid 20317744)
15. Frøkjaer TO, Ladefoged J. Castleman's disease with renal infiltration by polyclonal plasma cells. Clin Nephrol 1998;49:328-330. (Pubitemid 28220992)
16. Lui SL, Chan KW, Li FK, et al. Castleman's disease and mesangial proliferative glomerulonephritis: the role of interleukin-6. Nephron 1998;78:323-327.
17. Miadonna A, Salmaso C, Palazzi P, et al. Fibrillary glomerulonephritis in Castleman's disease. Leuk Lymphoma 1998;28:429-435. (Pubitemid 28105051)
18. Sugimoto T, Ito J, Takeda N, et al. A case of castleman's disease complicated with nephrotic syndrome due to glomerulopathy mimicking membranoproliferative glomerulonephritis. Am J Med Sci 2008;335:495-498.
19. Rojas R, Martin C, Roman J, et al. Autoimmune haemolytic anaemia presenting 9 years prior to Castleman's disease. Br J Haematol 1994;86:431-432. (Pubitemid 24199024)
20. Liberato NL, Bollati P, Chiofalo F, et al. Autoimmune hemolytic anemia in multicentric Castleman's disease. Haematologica 1996;81:40-43. (Pubitemid 28020253)
21. Lerza R, Castello G, Truini M, et al. Splenectomy induced complete remission in a patient with multicentric Castleman's disease and autoimmune hemolytic anemia. Ann Hematol 1999;78:193-196. (Pubitemid 29201732)
22. Quinn JP, Gilligan OM, Horgan M. Evan's syndrome complicating multicentric Castleman's disease - dramatic response to rituximab. Eur J Haematol 2004;73:384-385. (Pubitemid 39349922)
23. D'Arena G, Cascavilla N. Chronic lymphocytic leukemiaassociated autoimmune hemolytic anemia. Leuk Lymphoma 2007;48:1072-1080. (Pubitemid 47009197)
24. Galletti J, Cañones C, Morande P, et al. Chronic lymphocytic leukemia cells bind and present the erythrocyte protein band 3: possible role as initiators of autoimmune hemolytic anemia. J Immunol 2008;181:3674-3683.
25. Soulier J, Grollet L, Oksenhendler E. Molecular analysis of clonality in Castleman's disease. Blood 1995;86:1131-1138.
26. Hanson CA, Frizzera G, Patton DF, et al. Clonal rearrangement for immunoglobulin and T-cell receptor genes in systemic Castleman's disease. Association with Epstein-Barr virus. Am J Pathol 1988;131:84-91.
27. Hall PA, Donaghy M, Cotter FE, et al. An immunohistological and genotypic study of the plasma cell form of Castleman's disease. Histopathology 1989;14:333-346. (Pubitemid 19129375)
28. Ohyashiki JH, Ohyashiki K, Kawakubo K, et al. Molecular genetic, cytogenetic, and immunophenotypic analyses in Castleman's disease of the plasma cell type. Am J Clin Pathol 1994;101:290-295. (Pubitemid 24089574)
29. Beck JT, Hsu SM, Wijdenes J, et al. Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994;330:602-605. (Pubitemid 24065794)
30. Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000;95:56-61. (Pubitemid 30017224)
31. Matsuyama M, Suzuki T, Tsuboi H, et al. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Intern Med 2007;46:771-774. (Pubitemid 46902277)
32. Lee FC, Merchant SH. Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. Am J Hematol 2003;73:48-53. (Pubitemid 36504579)
33. Menegato MA, Canelles MF, Tonutti E, et al. Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease. Clin Nephrol 2004;61:352-356. (Pubitemid 38579022)
34. Starkey CR, Joste NE, Lee FC. Near-total resolution of multicentric Castleman disease by prolonged treatment with thalidomide. Am J Hematol 2006;81:303-304.
35. Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 2001;98:3473-3475.
36. Gérard L, Bérezné A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol 2007;25:3350-3356. (Pubitemid 47325622)
37. Hess G, Wagner V, Kreft A, et al. Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease. Br J Haematol 2006;134:544-545. (Pubitemid 44141721)
38. Chang Y, Cesarman, E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-1869.
39. Guihot A, Oksenhendler E, Galicier L, et al. Multicentric Castleman disease is associated with polyfunctional effector memory HHV-8-specific CD8+T cells. Blood 2008;111:1387-1395. (Pubitemid 351213425)